Company / Financials
CNBX Pharmaceuticals Inc. Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2025 · -100.0% YoY
Net Income
-$314.0K
FY2025 · +54.8% YoY
Profit Margin
-
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$18.4K
FY2025
Total Debt
-
FY2025
Equity
-$2.5M
FY2025
ROA
-1703.0%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -1304.12 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0-100.0% YoYNet Income HistoryProfit after all expenses and taxes-$314.0K+54.8% YoYGross Profit HistoryRevenue minus cost of goods sold-Operating Income HistoryProfit from core business operations before interest and taxes-$271.7K+53.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$271.7K-47.6% YoYR&D Expense HistoryResearch and development spending$0-100.0% YoYInterest Expense HistoryCost of borrowing and debt obligations$39.8KEPS (Basic) HistoryBasic earnings per share-$0.02+95.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.02+95.2% YoYShares Outstanding HistoryWeighted average diluted shares outstanding31.1M+37.6% YoY